Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2017-02-02

Clinical Trial Update: Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating clonidine for sleep disturbances in children with autism spectrum disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Clonidine (clonidine)

Snippet

Sponsor: Ohio State University | Conditions: Autism Spectrum Disorder | Phase 2 | Status: WITHDRAWN